Key Takeaways
- Deep cyclical trough, not structural damage: Revenue fell 10% and EBITDA 29% as Chinese oversupply, global destocking and weak discretionary demand converged. Management frames this as a prolonged but finite inventory cycle, not a demand destruction event.
- Inventory correction is the dominant story: The agrochemical value chain alone held ~8–9 months of inventory on a $75 bn market; high dollar interest rates are forcing that down to 2–3 months, a process expected to settle by calendar year-end.
- Long-term contracts provide a floor, not immunity: The second LT contract delivers EBITDA irrespective of volume, but the dicamba contract is severely impaired and may force a plant repurposing decision within 1–2 quarters.
- Capex cycle stays on track: ₹260 crore spent this quarter, $130 mn IFC funding secured, and the chlorotoluene project (₹1,500 crore first phase) targets FY26 commissioning, signalling conviction beyond the trough.
- What to watch next quarter: Whether customer volume indications for Q3/Q4 actually convert into orders, the dicamba plant decision, and any stabilization in the PDA and polymer-additive segments.
The Inventory Destocking Cycle
- Scale of the overhang: The agrochemical chain accumulated inventory over two years of container shortages, then faced a sudden spike in carrying costs as dollar rates hit 7–8%. Customers who once held 3 months of stock are now compressing to 2 months, and some stopped buying entirely for 3 months.
- Duration compared to history: Management likens this to the 2008 cycle, which lasted two quarters, but calls this one "slower and more prolonged." The correction is expected to settle by the end of this calendar year, with a new inventory normal emerging around that time.
- Customer signals are turning: Several customers who had stopped buying have now provided volume indications for October through March, suggesting the destocking phase is nearing its end and restocking could begin in H2.
- Structural demand intact: End-use consumption in pharma, agro, paints and autos has not been replaced by new chemicals; the underlying need persists, and management argues the China-plus-one story will keep Indian volumes relevant once the cycle turns.
Rajendra Gogri: "Structurally, the chemicals are required by the end user, whether it is pharma, agro, or for paint or car or all the end users, there is no change. There are no new chemicals which have come in."
Segment-Level Pain Points
| Segment | Trend | Commentary |
|---|---|---|
| PDA (domestic dyes, export polymers) | ▼ Worst hit | Polymer-side correction started more recently, causing a sharp decline; domestic dye demand remains weak. |
| Textiles | ▼ Prolonged weakness | Started getting impacted in FY23 and still not showing any significant increase. |
| Pigments | ▬ Bottoming out | Some green shoots possible from Q2 onwards; appears to have reached a floor. |
| Polymers & additives | ▼ Late-cycle correction | Corrections started more recently; may bottom out only toward Q3–Q4. |
| Nitrotoluene | ▲ Strong Q1, then ▼ | Strong Q1 volumes driven by agro demand, but Q2 and Q3 will see subdued numbers due to inventory correction. |
| Pharma (30% of domestic) | ▬ Stable | No change in demand; China has been aggressive in exporting to India in this segment. |
- Margin pressure is tiered: Base chemicals face more margin compression than value-added products, but the volume impact is indiscriminate across specialty, value-added and base chemicals.
- Chinese currency adds to the squeeze: A ~4% depreciation of the Chinese yuan against the Indian rupee has intensified price pressure on products where domestic competition comes from Chinese imports.
Long-Term Contracts: Asymmetric Exposure
- Second LT contract (structural): EBITDA is assured irrespective of volume movement, providing a genuine floor. The contract has kicked in and absolute EBITDA is virtually not going to change much.
- Dicamba contract (severely impaired): The first long-term contract, tied to a dicamba intermediate, has been severely impacted by demand slowdown in that product line. The plant is a specialized continuous facility, difficult to repurpose for other products.
- Repurposing decision ahead: Management will decide within the next 1–2 quarters whether to make a substantial modification to the facility and introduce new products; one of the two lines may be repurposed.
- Third LT contract (ramping): On stabilization and has good demand visibility; the second half of the year is expected to show good numbers.
Rajendra Gogri: "It's a very specialized plant; it's a continuous plant and difficult to use for other products. But we will take a call on that, maybe in the next 1 or 2 quarters, on whether we can really make a substantial modification in that facility and introduce new products because we have 2 different lines there; maybe 1 line we can repurpose or so."
Margin & Profitability Mechanics
- Gross margin at a trough: Q1 gross margin of ~35% was described as "weakest ever possibly," but management cautions that benzene price declines inflate the percentage optically; absolute gross profit and EBITDA are better measures.
- Raw material pass-through timing: Domestic market passes through raw material costs month-to-month; exports carry a quarterly lag. Raw material prices have started rising after a downward trend in June–July, which may support top-line recovery.
- Other expenses volatile: Ocean freight, a substantial component of other expenses, has seen sharp corrections that introduce volatility into cost structures.
- Tax rate tailwind: A likely sub-10% tax rate this year will cushion the PBT-to-PAT conversion, and a substantial jump at the PBT level is possible toward the end of Q4.
Capex, Balance Sheet & Liquidity
- Capex spend this quarter: Over ₹260 crore undertaken, with a plan to spend ₹2,500–3,000 crore over the next two years to elevate manufacturing capabilities and expand the value-added portfolio.
- IFC funding secured: $130 million in long-tenure money from IFC for new capex initiatives, diversifying the funding base.
- Chlorotoluene project: 42,000-tonne base capacity with downstream chemistries; first phase ~₹1,500 crore capex; most commissioning in FY26, some potentially slipping to FY27.
- Nitrotoluene and ethylation block: Targeting commissioning in Q1 FY25.
- NCB capacity expansion: Scale-up from 75,000 TPA to 108,000 TPA completed recently; new PNCB capacity also came up this month, which will help reduce imports from China.
- Debt comfort: Annual debt repayment of roughly ₹350 crore can be easily managed from current cash flows; working capital contraction from lower revenues will release additional cash. Debt-to-equity is targeted at 0.56–0.6x, with a worst case of 0.7x.
Demand Recovery: The H2 Bet
- Q2 expected to stay subdued: EBITDA is expected in a similar range (~₹200 crore), with some agrochemical lines like nitrotoluene already showing a Q2 slowdown.
- Recovery concentrated in H2: Volume recovery is expected to kick in gradually from the second half, weighted more toward Q3 and Q4 than Q2. Customer indications point to higher volumes in Q3 and still higher in Q4.
- Volume growth reset: Instead of the earlier 25% growth expectation, overall volume growth may land around 10% for the year.
- New projects delayed by the cycle: New multipurpose plants and specialty chemical units are now expected to ramp up more toward the end of FY25 due to the inventory correction, pushing the growth contribution from these assets further out.
- Domestic demand a steady anchor: The 30% of business going into pharmaceutical applications and other domestic end-markets shows fairly stable demand with no significant destocking issue.
Rajendra Gogri: "A lot of customers have given guidance and an indication on the kind of material they will need from October to March. We have received this for a lot of customers who were not buying. Some of them were not buying for 3 months also."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume recovery | Gradual recovery, weighted to Q3 and Q4 over Q2 | H2 FY24 |
| Inventory correction completion | Destocking settles; new inventory normal established | End of calendar year 2023 |
| Q2 EBITDA | Similar range to Q1 (~₹200 crore) | Q2 FY24 |
| Dicamba plant decision | Call on substantial modification and product repurposing | Next 1–2 quarters |
| Chlorotoluene commissioning | First phase (~₹1,500 crore capex) on stream | FY26 (some possibly FY27) |
| Nitrotoluene & ethylation block commissioning | New capacity operational | Q1 FY25 |
| Tax rate | Sub-10% | FY24 |
| Debt-to-equity | 0.56–0.6x target; 0.7x worst case | Ongoing |
| Annual debt repayment | ~₹350 crore, managed from current cash flows | Ongoing |
| FY25 EBITDA (previous ₹1,700 crore guidance) | Decline of 5–10% or a little more possible; clarity in next couple of quarters | FY25 |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | ₹1,571 cr, declined 10% YoY |
| EBITDA | ₹201 cr, down 29% YoY |
| EBITDA margin | 14% |
| Profit after tax | ₹70 cr |
| CAPEX during the quarter | over ₹260 cr |
| Expected CAPEX over next two years | ₹2,500–3,000 cr |
| Net debt | ~₹2,650 cr; gross debt ~₹3,000 cr, cash surplus ~₹400 cr |
| Net debt-to-equity | 0.56; peak target 0.6–0.7, worst-case outer limit 0.7 |
| Direct export share | 45% to 50%; indirect export 20% to 25%, 70% of business linked to international market |
| Nitrochlorobenzene production | 17,293 MT, vs 20,515 MT in Q1 FY23 |
| Nitro-Toluene production | 9,327 MT, vs 5,252 MT in Q1 FY23 |
| Hydrogenation production | 2,868 TPM, vs 3,295 TPM in Q1 FY23 |
| PDA production | 135 tonnes per month, vs 371 tonnes per month in Q1 FY23 |
| NCB capacity expansion | completed, from 75,000 TPA to 108,000 TPA |
| Annual debt repayment | ~₹350 cr |
| IFC long-tenure funding secured | $130 million for new CAPEX initiatives |